domvanalimab,etrumadenant,zimberelimab
otsuka,arcus biosciences,gilead
['etrumadenant', 'zimberelimab', 'nsclc', 'domvana', 'sclc', 'lcsm,(-blcsm)', 'arc-7']
updated arc-7: randomized ph2 study of domvanalimab + zimberelimab etrumadenant vs zimberelimab in 1l pd-l1-high mnsclc by clinical activity of anti pd-1 + tigit combinations vs anti pd-1 (zim) alone. #asco2023 #nsclc #lcsm #io 
Medical Oncology, Thoracic Oncology @incanMX / CánCare • Hospital Ángeles del Carmen / Opinions my own